New insights into the biology and diagnosis of splenic marginal zone lymphomas
M Donzel, L Baseggio, J Fontaine, F Pesce… - Current …, 2021 - mdpi.com
Splenic marginal zone lymphoma (SMZL) is a small B-cell lymphoma, which has been
recognized as a distinct pathological entity since the WHO 2008 classification. It classically …
recognized as a distinct pathological entity since the WHO 2008 classification. It classically …
Targeting IRAK4 with emavusertib in lymphoma models with secondary resistance to PI3K and BTK inhibitors
Inhibitors of phosphatidylinositol 3-kinase (PI3K) and Bruton tyrosine kinase (BTK) represent
a recognized option for the treatment of patients affected by indolent B cell lymphomas …
a recognized option for the treatment of patients affected by indolent B cell lymphomas …
Heterozygous premature termination in zinc-finger domain of Krüppel-like factor 2 gene associates with dysregulated immunity
N Pernaa, S Keskitalo, I Chowdhury… - Frontiers in …, 2022 - frontiersin.org
Krüppel-like factor 2 (KLF2) is a transcription factor with significant roles in development,
maturation, differentiation, and proliferation of several cell types. In immune cells, KLF2 …
maturation, differentiation, and proliferation of several cell types. In immune cells, KLF2 …
[HTML][HTML] Targeting pathogenic mechanisms in marginal zone lymphoma: from concepts and beyond
JK Lue, OA O'Connor, F Bertoni - Annals of lymphoma, 2020 - ncbi.nlm.nih.gov
Marginal zone lymphoma (MZL) represents a group of three distinct though overlapping
lymphoid malignancies that includes extranodal, nodal and splenic marginal lymphoma …
lymphoid malignancies that includes extranodal, nodal and splenic marginal lymphoma …
[HTML][HTML] Clinical characteristics, treatment patterns, and survival outcomes of pulmonary mucosa-associated lymphoid tissue lymphoma in the United States
H Lin, Z Li, Y Wu, H Wang - American Journal of Translational …, 2023 - ncbi.nlm.nih.gov
Background: Pulmonary mucosa-associated lymphoid tissue (MALT) lymphoma is a
relatively rare disease. We aimed to perform a large-scale study of clinical characteristics …
relatively rare disease. We aimed to perform a large-scale study of clinical characteristics …
Rare lymphomas in routine practice–Treatment and outcome in marginal zone lymphoma in the prospective German Tumour Registry Lymphatic Neoplasms
W Knauf, W Abenhardt, M Koenigsmann… - Hematological …, 2021 - Wiley Online Library
Owing to its heterogeneity and rarity, management of disseminated marginal zone B‐cell
lymphoma (MZL) remains largely understudied. We present prospective data on choice of …
lymphoma (MZL) remains largely understudied. We present prospective data on choice of …
[HTML][HTML] Identification of six hub genes in mantle cell lymphoma patients with BTKi resistance
S Liu, P Yang, L Wang, C Li, W Zhang… - Annals of …, 2022 - ncbi.nlm.nih.gov
Background Bruton tyrosine kinase inhibitor (BTKi) resistance is an unsolved problem in the
treatment of relapse/recurrence (R/R) mantle cell lymphoma (MCL). Although salvage …
treatment of relapse/recurrence (R/R) mantle cell lymphoma (MCL). Although salvage …
Anti-CD20 rechallenge with ofatumumab in relapsed/refractory splenic marginal zone lymphoma: the MORE trial
L Scarfò, S Ferrari, AM Frustaci, M Tani, A Bari… - Blood …, 2022 - ashpublications.org
COI notes: LS received honoraria from AbbVie, AstraZeneca and Janssen outside the
submitted work. AJMF received speaker fees from Adienne, Gilead; research grants from …
submitted work. AJMF received speaker fees from Adienne, Gilead; research grants from …
Identifying genetic factors in familial lymphoid cancers
S Ralli - 2024 - summit.sfu.ca
Lymphoid cancer is a common hematological malignancy worldwide, accounting nearly 5%
of all cancers. It is the fifth most prevalent cancer and has the sixth highest mortality among …
of all cancers. It is the fifth most prevalent cancer and has the sixth highest mortality among …